[144] IONIS PHARMACEUTICALS INC SEC Filing

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS, INC. (IONS) submitted a Form 144 reporting a proposed sale of 27,114 shares of common stock through Stifel Nicolaus & Company on Nasdaq, with an aggregate market value of $1,789,524 and total shares outstanding reported as 159,391,229. The filer reports acquiring 17,114 of these shares on 01/15/2021 by option exercise, with payment listed as cash and an approximate sale date of 10/01/2025.

The filing also discloses a prior sale by the same person on 09/02/2025 of 11,130 shares for $552,865. By simple proportion, the proposed sale represents approximately 0.017% of outstanding shares, indicating the transaction is small relative to the company's share count. The notice contains the standard insider representation about absence of undisclosed material information.

Positive

• Compliance disclosure provided with broker, share counts, aggregate value, acquisition method and prior sale details
• Full transparency about acquisition date (01/15/2021) and nature (option exercise), facilitating investor review

Negative

• Insider selling is disclosed (proposed sale of 27,114 shares and prior sale of 11,130 shares), which some investors may view negatively even though scale is small

Insights

Securities Compliance Analyst

TL;DR Routine Rule 144 filing documenting a small insider sale and prior recent disposition; consistent with compliance obligations.

This Form 144 supplies required details: broker, number of shares proposed, aggregate value, acquisition method (option exercise), and a prior sale within the past three months. The filing helps ensure the seller meets resale conditions under Rule 144 and provides market transparency. No indication in the form of undisclosed material information is provided by the signer, which is standard and required. The proposed sale size (~0.017% of outstanding shares) is immaterial from a market-impact perspective.

Equity Research Analyst

TL;DR Insider sale disclosed but quantitatively negligible versus total shares outstanding; unlikely to change investor valuation materially.

The reported aggregate value ($1.79M) and prior gross proceeds ($552.9k) give transparency on insider liquidity. The acquisition date and method (01/15/2021, option exercise) explain the origin of the shares sold. Given the small percentage of outstanding shares being sold, this notice appears informational rather than signaling a material shift in insider conviction. Investors may note the timing and aggregation of recent sales but the scale is not significant relative to market capitalization based on reported outstanding shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	27114	1789524.00	159391229	10/01/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2021	Option Exercise	Issuer			17114	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
2855 Gazelle Ct Carlsbad 92010 CA 92010	Common Stock	09/02/2025	11130	552865.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by IONS report?

The form reports a proposed sale of 27,114 common shares through Stifel Nicolaus on Nasdaq with an aggregate market value of $1,789,524 and an approximate sale date of 10/01/2025.

How many shares did the filer acquire and how were they acquired?

The filing states 17,114 shares were acquired on 01/15/2021 by option exercise and payment is listed as cash.

Did the filer sell any shares recently prior to this proposed sale?

Yes. The filer sold 11,130 shares on 09/02/2025 for gross proceeds of $552,865.

How material is the proposed sale relative to outstanding shares?

Based on the filing's reported outstanding shares (159,391,229), the proposed sale of 27,114 shares is approximately 0.017% of outstanding shares, indicating a negligible market impact.

Who is handling the sale according to the filing?

The broker named on the Form 144 is Stifel Nicolaus & Company Inc, located in St. Louis, MO.